Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

CURIS- Time to Assess Value Beyond Erivedge!

Enquire | Email | Print

Published Date: Feb, 2013
Format: PDF
No of Pages: 7
 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Oral PI3K, BTK, Bcl-2 inhibitors are set to bring a change in treatment paradigm of hematological malignancies (CLL, iNHL, ALL). Curis’s (CRIS) pipeline consists of a marketed drug Erivedge (L in US, R in EU/other, vismodegib, HedgeHog pathway inhibitor) and CUDC-907 (PI3K/HDAC dual inhibitor, PhI) in PhI besides other products. BTK, PI3K and HDAC are clinically validated targets for treating leukemia’s. Current SoC includes IV/SC mAbs (Rituxan/MabThera, Arzerra) in combinations with chemotherapy. There remains an unmet need for pts who are resistant or can not tolerate these treatment options.

There are not too many unpartnered PI3K inhibitors in the pipeline and early promising data could trigger………. For more details, please read our report released on 11th February. 2013 on CRIS titled “Time to Assess Value Beyond Erivedge!


Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 372902, price: INR 8486, MP Advisors

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online